As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage.
By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a company working in healthcare, with a specific emphasis on Johnson & Johnson’s sectors: consumer, medical device and pharmaceuticals.
What would you ask an entrepreneur who’s led multiple biotechs from founding to multi-million dollar exits? Enjoy your morning coffee while hearing from Mike Gilman, currently CEO and Chairman of Arrakis, a Boston based company developing small molecules to drug RNA (and just closed a $75M series B!) Mike was previously founder and CEO of Padlock Therapeutics, an autoimmune disease focused company with a presence in San Diego, which was acquired in 2016 with a deal of up to $600M. He also recently worked at Biogen Idec, after it acquired Stromedix - where he was founder and CEO - in a deal of up to $562M. Don’t miss Mike’s visit to San Diego to share his stories and insights with the innovation community.
Â
Join Johnson & Johnson Innovation, JLABS and CLSA for an intimate fireside chat style breakfast session with Mike Gilman, Boston-based entrepreneur. Bring your questions!
Dr. Gilman is CEO of Arrakis and Chairman of the Board of Directors. In addition, Mike currently serves on the Board of Directors of Novartis Venture Fund, Obsidian Therapeutics, and Scholar Rock and on the Scientific Advisory Board of FutuRx.
Previously, Mike was Chief Executive Officer of Obsidian Therapeutics, a venture-funded company focused on applying synthetic biology to gene and cell therapies.
Â
Â
Iman Famili is the President and Acting CEO of Sinopia Biosciences, a leader in computational drug repurposing in San Diego. Prior to Sinopia, she served as the Executive Director/VP of Cell Systems Informatics at Intrexon, a leader in synthetic biology. She was a founding member at GT Life Sciences, a systems biology company focused on improving protein production in mammalian cell lines that was successfully acquired. She is an inventor on 16 patents and patent applications. Iman received her Ph.D. in Bioengineering with Specialization in Bioinformatics from University of California, San Diego.
